Cisco
CompTIA
ISC
EC-Council
EXIN
Fortinet
ITIL
Juniper
Microsoft
VMware
Avaya
SAP
Google
NVIDIA
Salesforce
Amazon
Palo Alto Networks
ISC2
Splunk
ServiceNow
All Vendors
  2. Home
  3. Exams
  4. USMLE
  5. STEP2

USMLE STEP2 Exam
Step2 (Page 21 )

Updated On: 30-Jan-2026
Page 21 of 149
PDF with 738 Questions

For the screening tests listed below, select the screening schedule that is appropriate for women (as per the U.S. Preventive Services Task Force [USPSTF], The Guide to Clinical Preventive Services, 2006) Cervical cytology (Pap smear)

  1. do not routinely screen
  2. yearly over age 50
  3. at first prenatal visit
  4. every 12 years at age 40 and older
  5. every 12 years at age 50 and older
  6. every 3 years following an initial examination, but not after age 65
  7. every 3 years at age 50 and older

Answer(s): F

Explanation:

The USPSTF strongly recommends screening for cervical cancer (Pap smear) at least every 3 years in women who have been sexually active or are 21 years old, and have a cervix. It recommends against screening after a normal hysterectomy, or after age 65, if recent Pap smears were normal and the woman is not at high risk. (Note: Although evidence is still considered insufficient, screening for human papilloma virus [HPV] infection shows promise as a part of cervical cancer prevention. Vaccination against HPV is expected to greatly decrease the incidence of cervical cancer in the future.)



For the screening tests listed below, select the screening schedule that is appropriate for women (as per the U.S. Preventive Services Task Force [USPSTF], The Guide to Clinical Preventive Services, 2006) Fecal occult blood testing (FOBT)

  1. do not routinely screen
  2. yearly over age 50
  3. at first prenatal visit
  4. every 12 years at age 40 and older
  5. every 12 years at age 50 and older
  6. every 3 years following an initial examination, but not after age 65
  7. every 3 years at age 50 and older

Answer(s): E

Explanation:

The USPSTF strongly recommends that men and women aged 50 or older be screened for colorectal cancer. Various methods exist for screening and the optimal interval for screening varies based on the method of screening. Current options for screening average risk individuals include FOBT every 12 years, sigmoidoscopy every 5 years, colonoscopy every 10 years, and other tests. Higher-risk individuals, those with a first-degree relative with a diagnosis of colon cancer before age 60, should receive screening at an earlier age and at shorter intervals.



For the screening tests listed below, select the screening schedule that is appropriate for women (as per the U.S. Preventive Services Task Force [USPSTF], The Guide to Clinical Preventive Services, 2006)

Screening for hepatitis B

  1. do not routinely screen
  2. yearly over age 50
  3. at first prenatal visit
  4. every 12 years at age 40 and older
  5. every 12 years at age 50 and older
  6. every 3 years following an initial examination, but not after age 65
  7. every 3 years at age 50 and older

Answer(s): C

Explanation:

The USPSTF strongly recommends screening pregnant women for hepatitis B at their first prenatal visit, but recommends against screening the general population.



For the screening tests listed below, select the screening schedule that is appropriate for women (as per the U.S. Preventive Services Task Force [USPSTF], The Guide to Clinical Preventive Services, 2006) Palpation, ultrasound, or serologic testing of the abdomen to screen for cancer of the pancreas

  1. do not routinely screen
  2. yearly over age 50
  3. at first prenatal visit
  4. every 12 years at age 40 and older
  5. every 12 years at age 50 and older
  6. every 3 years following an initial examination, but not after age 65
  7. every 3 years at age 50 and older

Answer(s): A

Explanation:

The USPSTF recommends against routine screening for pancreatic cancer in asymptomatic adults



From the below the clinical indications, choose an option for use of immune globulin (IG) in Hepatitis A prophylaxis

  1. indicated
  2. not proven effective
  3. not routinely indicated
  4. contraindicated
  5. compulsory

Answer(s): A

Explanation:

IG given before exposure or within 14 days of exposure is 7585% effective in preventing symptomatic illness from hepatitis A. IG is produced from the plasma of normal adults and does not contain sufficient antibody to prevent hepatitis B infection. Hepatitis B immune globulin (HBIG) is prepared from plasma known to contain high antibody titers for hepatitis B surface antigen (HBsAg) and is specific for hepatitis B.
Given immediately postexposure, and again 1 month later, it has a combined efficacy of about 75% in the prevention of hepatitis B. Postexposure IG has not been found effective in the prevention of hepatitis C infection; on the other hand, treatment of early hepatitis C infection is possible, and thus it is important to monitor exposed individuals to determine whether infection occurs. IG administered to individuals exposed to measles infection who are susceptible to the disease has been shown to be effective if given within 6 days of exposure.
Recent use of IG is a contraindication to immunization with rubella vaccine. IG is not very effective at preventing in utero infection with rubella, and infants with congenital rubella syndrome have been born to women given IG shortly after exposure. IG is not routinely indicated, as it is indicated only if abortion is not elected.



Viewing page 21 of 149
Viewing questions 101 - 105 out of 738 questions



Post your Comments and Discuss USMLE STEP2 exam prep with other Community members:

Join the STEP2 Discussion